Overview

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Patients With ALK-Positive or ROS1-Positive Solid Tumors

Status:
Completed

Trial end date:
2021-04-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.

Phase:

Phase 1

Details

Lead Sponsor:

Ariad Pharmaceuticals

Treatments:

Midazolam